Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
$1.25
-3.9%
$1.29
$0.65
$3.80
$16.57M0.663.93 million shs196,250 shs
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$0.82
-0.7%
$0.95
$0.59
$8.60
$17.09M0.56128,282 shs9,315 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.10
-90.0%
$0.96
$0.00
$7.61
$480K0.447,198 shs280 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.48
+1.4%
$1.38
$0.90
$1.96
$17.32M0.5226,747 shs35,515 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
0.00%+1.56%+1.56%+52.22%+71.28%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00%+6.28%-27.91%-22.60%-81.37%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%+354.55%-90.00%-94.74%+9,999,900.00%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%-1.35%-8.18%+29.20%-2.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
2.6001 of 5 stars
3.55.00.00.01.60.00.6
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.295 of 5 stars
0.03.00.04.40.80.00.0
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
3.00
Buy$4.00220.05% Upside
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORGS, SYBX, LSB, and HOTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/30/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/23/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/26/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/12/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/A$0.86 per shareN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$85.67M0.20N/AN/A$3.35 per share0.25
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K0.72N/AN/A($6.58) per share-0.02
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/A$1.09 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
-$13.93MN/A0.00N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A-8.09%-5.50%11/11/2025 (Estimated)

Latest ORGS, SYBX, LSB, and HOTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$0.27-$0.17+$0.10-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/A
27.54
27.54
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.05
1.02
0.75
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.63
3.63

Institutional Ownership

CompanyInstitutional Ownership
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
7.08%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
52.64%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
6.92%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
413.26 million12.34 millionNot Optionable
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
77320.77 millionN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.35 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hoth Therapeutics stock logo

Hoth Therapeutics NASDAQ:HOTH

$1.25 -0.05 (-3.86%)
Closing price 03:59 PM Eastern
Extended Trading
$1.25 +0.00 (+0.02%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

LakeShore Biopharma stock logo

LakeShore Biopharma NASDAQ:LSB

$0.82 -0.01 (-0.72%)
Closing price 03:59 PM Eastern
Extended Trading
$0.84 +0.01 (+1.58%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$0.10 -0.90 (-90.00%)
As of 09:30 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.48 +0.02 (+1.03%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.